cc-292 and Lymphoma--Mantle-Cell

cc-292 has been researched along with Lymphoma--Mantle-Cell* in 1 studies

Other Studies

1 other study(ies) available for cc-292 and Lymphoma--Mantle-Cell

Article	Year
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status. Haematologica, 2017, Volume: 102, Issue:11 Topics: Acrylamides; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thalidomide	2017

Article

Year

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Haematologica, 2017, Volume: 102, Issue:11

Topics: Acrylamides; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thalidomide

2017